Why Menopause Matters in Substance Use Disorder Prevention, Treatment, and Recovery
Impact on your practice
This is clinical guidance rather than policy, useful for therapists working with midlife women but doesn't directly impact licensing, reimbursement, or practice operations.
Key facts
Examines connection between menopause, hormonal changes, and substance use disorder risk
Addresses gap in clinical education on sex/gender-specific factors in SUD
Relevant to therapists treating midlife women with co-occurring conditions
Therapy Companion analysis
This federal guidance establishes menopause as a clinically significant risk factor in substance use disorder (SUD) prevention, treatment, and recovery—a shift that will directly affect your assessment protocols and treatment planning, particularly if you serve women ages 40–65. While not a mandate, SAMHSA's first-ever symposium on menopause-informed SUD care (May 2026) signals that payers, accreditors, and regulators will increasingly expect documentation of menopause screening and symptom management in your treatment records for midlife women with SUD or co-occurring mood/sleep disorders. You should anticipate that your electronic health record (EHR) templates for SUD and mood disorder assessments will need to include explicit screening for menopause stage, duration of hormonal transition symptoms, and the bidirectional relationship between sleep disturbance, mood instability, and substance use escalation. This is operationally significant because inadequate menopause screening in a woman's recovery could later become a liability issue if relapse occurs during the perimenopause window. For agencies and group practices, this guidance justifies adding training on sex-specific SUD risk factors to your clinical supervision and continuing education budget. There is no immediate reimbursement change tied to this guidance, but the emphasis on integrated behavioral health and obstetric/gynecology collaboration may create referral opportunities and justify billing for care coordination (CPT 99490–99492) when you're coordinating SUD treatment with primary care or women's health providers managing menopausal symptoms.
Background
SAMHSA has historically emphasized gender-informed SUD treatment, but menopause has been largely absent from clinical guidelines, workforce training curricula, and prevention frameworks despite evidence that hormonal transitions alter substance use trajectories. This guidance addresses a documented gap: women in recovery face elevated relapse risk during perimenopause and postmenopause due to sleep disruption, anxiety, depression, and pain—symptoms they may attempt to self-medicate with alcohol, cannabis, or prescription opioids. The federal focus reflects both emerging neurobiological research on estrogen's role in dopamine regulation and reward sensitivity, and demographic urgency: the U.S. Census Bureau projects over 51 million women will be in the menopausal transition by 2030. Prior to this May 2026 guidance, most SUD treatment protocols did not differentiate risk or treatment response by menopausal status, and primary care, OB/GYN, and behavioral health providers operated in silos regarding midlife women's care. This document signals that coordinated, sex-specific SUD care is now a federal priority area, positioning menopause-informed practice as an emerging standard of care expectation.
What you should do
Revise your SUD and mood disorder intake assessment forms to include explicit screening questions for menopause stage (perimenopausal vs. postmenopausal), duration of symptoms, and whether sleep disturbance, anxiety, or pain are being managed with alcohol or other substances. Document the bidirectional relationship in your treatment plan.
If you work in an agency or group setting, add menopause-informed SUD care to your clinical supervision and staff training agenda within the next 6–12 months, using SAMHSA's resources and the symposium outcomes (expected to be published through SAMHSA.gov by late 2026) as your reference materials.
Establish or strengthen referral relationships with primary care and OB/GYN providers so you can coordinate care for midlife women with SUD and untreated menopause symptoms. Document these care coordination efforts in the chart to support medical necessity for extended or intensive treatment.
Review your EHR templates for SUD, depression, anxiety, and insomnia diagnoses to ensure that menopausal status is recorded. This supports accurate risk stratification and defensibility of treatment intensity if a payer questions the level of care.
Monitor SAMHSA announcements (samhsa.gov) and your licensing board's CE requirements over the next 12–24 months for emerging competency standards on sex-specific SUD treatment. Consider obtaining continuing education on hormonal factors in SUD before it becomes a compliance expectation.
Notable excerpts
"Emerging evidence shows that going through the menopause transition can influence substance use patterns, including a woman's risk of escalating substance use and recurrence after a period of recovery." — Berlina Wallace-Berube, SAMHSA Center for Substance Abuse Treatment
"Despite these challenges, menopause is not usually considered in substance use disorder prevention, screening, treatment, or recovery programs. This gap highlights the need for more awareness, better guidance for providers, and care that is tailored for women in midlife." — Federal guidance, SAMHSA
"Strengthening collaboration between behavioral health and women's health providers is also essential." — SAMHSA, May 2026
View full source text
Policy changes drive denial patterns
Therapy Companion tracks both: the policy shifts on this page and the denial patterns hitting your claims.
Related policy changes
A New Federal Interpretation Challenges the ‘Gold Standard’ of SMI Care
This DOJ memo could fundamentally reshape where and how community-based mental health services are funded and delivered. Therapists working in community-integrated programs or value-based models should monitor this closely, as it may affect referral patterns, funding models, and scope of practice in community settings.
Behavioral Health Billing Fraud, Kickbacks Totalled $208M in Massive DOJ Fraud Bust
This enforcement action underscores heightened scrutiny of behavioral health billing practices, particularly around rapidly-growing modalities like TMS. Therapists and practices should audit billing accuracy and documentation, especially in high-fraud areas. Overly aggressive billing practices or inadequate supervision documentation now carry real federal prosecution risk.
Advancing the Future of Behavioral Health Data Exchange
Better behavioral health data exchange is a regulatory and operational priority that will likely drive new EHR interoperability requirements and documentation standards for therapists. Understanding this movement helps practices anticipate compliance changes.
STAT+: Trump’s boosting of psychedelics, cannabis signal a new era in GOP drug policy
Federal marijuana rescheduling will complicate assessment, treatment planning, and documentation for therapists, particularly around substance use evaluation and dual diagnoses. Therapists in legal marijuana states will need updated clinical guidelines and liability coverage clarity.